These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 10517116)
1. [Increased thrombin time in a patient with multiple myeloma]. Bohler A; Redondo M; Lämmle B Ther Umsch; 1999 Sep; 56(9):491-4. PubMed ID: 10517116 [TBL] [Abstract][Full Text] [Related]
2. [Unexpectedly prolonged thrombin time]. Barth A; Furlan M; Lämmle B Schweiz Med Wochenschr; 1993 Mar; 123(12):523-9. PubMed ID: 8475358 [TBL] [Abstract][Full Text] [Related]
3. [Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma]. Lopaciuk S; Snigurowicz J; Rostkowska J; Pniejnia-Olszyński W; Powiertowska-Rezmer M Acta Haematol Pol; 1978; 9(3):157-64. PubMed ID: 102100 [TBL] [Abstract][Full Text] [Related]
5. An acquired cryoglobulinemia which inhibits fibrin polymerization in a patient with IgG kappa myeloma. Panzer S; Thaler E Haemostasis; 1993; 23(1):69-76. PubMed ID: 8477911 [TBL] [Abstract][Full Text] [Related]
6. Bleeding diathesis in multiple myeloma. Saif MW; Allegra CJ; Greenberg B J Hematother Stem Cell Res; 2001 Oct; 10(5):657-60. PubMed ID: 11672511 [TBL] [Abstract][Full Text] [Related]
7. Gamma globulin inhibition of fibrin clot formation. Davey FR; Gordon GB; Boral LI; Gottlieb AJ Ann Clin Lab Sci; 1976; 6(1):72-7. PubMed ID: 1247286 [TBL] [Abstract][Full Text] [Related]
8. Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency. Lee N; Kim JE; Yoo HJ; Gu J; Kim H; Chung J; Koh Y; Kim HK Ann Clin Lab Sci; 2016 Dec; 46(6):696-700. PubMed ID: 27993886 [TBL] [Abstract][Full Text] [Related]
9. Acquired dysfibrinogenemia secondary to mithramycin toxicity. Ashby MA; Lazarchick J Am J Med Sci; 1986 Jul; 292(1):53-5. PubMed ID: 2940861 [TBL] [Abstract][Full Text] [Related]
10. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Colwell NS; Tollefsen DM; Blinder MA Br J Haematol; 1997 Apr; 97(1):219-26. PubMed ID: 9136969 [TBL] [Abstract][Full Text] [Related]
11. Heparin-like anticoagulant associated with plasma cell myeloma. Chapman GS; George CB; Danley DL Am J Clin Pathol; 1985 Jun; 83(6):764-6. PubMed ID: 3923825 [TBL] [Abstract][Full Text] [Related]
12. The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer. Pengo V; Levi Minzi S; Dal Bo Zanon R; Cappellato G; Farinati F; Girolami A J Med; 1984; 15(2):149-60. PubMed ID: 6096471 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin. O'Kane MJ; Wisdom GB; Desai ZR; Archbold GP J Clin Pathol; 1994 Mar; 47(3):266-8. PubMed ID: 8163700 [TBL] [Abstract][Full Text] [Related]
14. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time. Van Cott EM; Smith EY; Galanakis DK Am J Clin Pathol; 2002 Aug; 118(2):263-8. PubMed ID: 12162688 [TBL] [Abstract][Full Text] [Related]
15. [Acquired dysfibrinogenemia in a child in the course of a liver disease]. Maak B; Meyer M; Dietze H Monatsschr Kinderheilkd; 1990 Aug; 138(8):446-50. PubMed ID: 2215508 [TBL] [Abstract][Full Text] [Related]
16. Fibrin polymerization defect in HIV-infected patients--evidence for a critical role of albumin in the prolongation of thrombin and reptilase clotting times. Toulon P; Frere E; Bachmeyer C; Candia N; Blanche P; Sereni D; Sicard D Thromb Haemost; 1995 Mar; 73(3):349-55. PubMed ID: 7667815 [TBL] [Abstract][Full Text] [Related]
17. A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange. Post GR; James L; Alapat D; Guillory V; Cottler-Fox M; Nakagawa M Transfus Apher Sci; 2013 Feb; 48(1):35-8. PubMed ID: 22842111 [TBL] [Abstract][Full Text] [Related]